Meixin Zheng, Yi Shao, Cong Gong, Yuting Wu, Weifang Liu, Min Chen
{"title":"Association between smoking status and sarcopenia among middle-aged and older adults: finding from the CHARLS study.","authors":"Meixin Zheng, Yi Shao, Cong Gong, Yuting Wu, Weifang Liu, Min Chen","doi":"10.1007/s41999-024-01101-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>There is limited information on the association between smoking/smoking cessation and sarcopenia in Chinese populations. We conducted a retrospective cohort study to investigate the association between smoking/smoking cessation and its duration with the risk of sarcopenia.</p><p><strong>Methods: </strong>This cohort included 6,719 adults over 45 from the CHARLS between 2011 and 2015. Smoking status was categorized into smokers (current smokers/quitters) and non-smokers. Duration of smoking was defined as < 20, 20-29, 30-39, and ≥ 40 years. Duration of smoking cessation was defined as ≤ 1, 2-4, and > 4 years. Sarcopenia was defined according to AWGS 2019. Cox proportional hazards regression models were used to estimate the hazard ratio for the risk of developing sarcopenia.</p><p><strong>Results: </strong>The median age of the cohort was 57.0 years, and 47.0% were male. Over a 3.7-year follow-up period, 9.7% of participants developed sarcopenia. Compared to non-smokers, smokers had a higher risk of developing sarcopenia (HR: 1.27, 95% CI 1.02-1.59). Among individuals with a smoking duration exceeding 40 years, the likelihood of developing sarcopenia was 39.0% higher (HR: 1.39, 95% CI 1.08-1.79). The elevated risk persists regardless of alcohol consumption. Quitters had a lower risk of sarcopenia compared to current smokers (HR: 0.67, 95% CI 0.47-0.97). Individuals who had quit smoking for > 4 years had a lower risk of sarcopenia compared to current smokers (HR: 0.43, 95% CI 0.24-0.78).</p><p><strong>Conclusion: </strong>Current smokers face a higher risk of sarcopenia, especially those with a prolonged smoking history. Promoting smoking cessation is an essential strategy for lowering the risk of sarcopenia and mitigating its burden among smokers.</p>","PeriodicalId":49287,"journal":{"name":"European Geriatric Medicine","volume":" ","pages":"79-88"},"PeriodicalIF":3.5000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Geriatric Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s41999-024-01101-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: There is limited information on the association between smoking/smoking cessation and sarcopenia in Chinese populations. We conducted a retrospective cohort study to investigate the association between smoking/smoking cessation and its duration with the risk of sarcopenia.
Methods: This cohort included 6,719 adults over 45 from the CHARLS between 2011 and 2015. Smoking status was categorized into smokers (current smokers/quitters) and non-smokers. Duration of smoking was defined as < 20, 20-29, 30-39, and ≥ 40 years. Duration of smoking cessation was defined as ≤ 1, 2-4, and > 4 years. Sarcopenia was defined according to AWGS 2019. Cox proportional hazards regression models were used to estimate the hazard ratio for the risk of developing sarcopenia.
Results: The median age of the cohort was 57.0 years, and 47.0% were male. Over a 3.7-year follow-up period, 9.7% of participants developed sarcopenia. Compared to non-smokers, smokers had a higher risk of developing sarcopenia (HR: 1.27, 95% CI 1.02-1.59). Among individuals with a smoking duration exceeding 40 years, the likelihood of developing sarcopenia was 39.0% higher (HR: 1.39, 95% CI 1.08-1.79). The elevated risk persists regardless of alcohol consumption. Quitters had a lower risk of sarcopenia compared to current smokers (HR: 0.67, 95% CI 0.47-0.97). Individuals who had quit smoking for > 4 years had a lower risk of sarcopenia compared to current smokers (HR: 0.43, 95% CI 0.24-0.78).
Conclusion: Current smokers face a higher risk of sarcopenia, especially those with a prolonged smoking history. Promoting smoking cessation is an essential strategy for lowering the risk of sarcopenia and mitigating its burden among smokers.
目的:在中国人群中,吸烟/戒烟与肌肉减少症之间的关联信息有限。我们进行了一项回顾性队列研究,以调查吸烟/戒烟及其持续时间与肌肉减少症风险之间的关系。方法:该队列包括2011年至2015年间来自CHARLS的6719名45岁以上的成年人。吸烟状况分为吸烟者(当前吸烟者/戒烟者)和非吸烟者。吸烟时间定义为4年。肌少症是根据AWGS 2019定义的。采用Cox比例风险回归模型估计发生肌肉减少症风险的风险比。结果:队列的中位年龄为57.0岁,47.0%为男性。在3.7年的随访期间,9.7%的参与者患上了肌肉减少症。与不吸烟者相比,吸烟者患肌肉减少症的风险更高(HR: 1.27, 95% CI 1.02-1.59)。在吸烟时间超过40年的个体中,发生肌肉减少症的可能性高出39.0% (HR: 1.39, 95% CI 1.08-1.79)。无论饮酒与否,这种增高的风险都会持续存在。与当前吸烟者相比,戒烟者患肌肉减少症的风险较低(HR: 0.67, 95% CI 0.47-0.97)。与目前吸烟者相比,戒烟40年以上的人患肌肉减少症的风险较低(HR: 0.43, 95% CI 0.24-0.78)。结论:当前吸烟者罹患肌肉减少症的风险较高,尤其是有长期吸烟史的吸烟者。促进戒烟是降低吸烟者肌肉减少症风险和减轻其负担的重要策略。
期刊介绍:
European Geriatric Medicine is the official journal of the European Geriatric Medicine Society (EUGMS). Launched in 2010, this journal aims to publish the highest quality material, both scientific and clinical, on all aspects of Geriatric Medicine.
The EUGMS is interested in the promotion of Geriatric Medicine in any setting (acute or subacute care, rehabilitation, nursing homes, primary care, fall clinics, ambulatory assessment, dementia clinics..), and also in functionality in old age, comprehensive geriatric assessment, geriatric syndromes, geriatric education, old age psychiatry, models of geriatric care in health services, and quality assurance.